All News
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Under the terms of the agreement, the companies plan to combine Kelonia's iGPS® with Xyphos' ACCEL™ technology to develop innovative in vivo CAR-T Cell therapies*2 targeting up to two programs.
Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Under these agreements, Brii Bio will issue a $2.5 million promissory note to VBI initially.
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
Shattuck will generate fusion proteins for certain targets using its proprietary protein engineering technologyand provide Ono with drug candidates for further optimization and clinical development.
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion.
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform
GSK enters exclusive license agreement with Hansoh for HS-20093
HS-20093 is currently being investigated in ongoing phase I and II trials in China.
“Windtree and Lee’s sign licence deal for heart failure therapy”
Windtree is entitled to receive $138.1m in milestone payments.
“Pan Orion Invests $415M in Korean Biotech LegoChem, Secures Majority Stake”
Once finalized, LegoChem will become part of Orion’s corporate family but will retain its current frameworks and management.
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients
OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.
